FIELD: biotechnology.
SUBSTANCE: invention relates to bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen such as CD3 and a bivalent arm specific to a second target antigen such as HER2, methods of their production and use. Also the following is provided: an isolated nucleic acid encoding a bispecific antigen-binding molecule, an expression vector, a host cell for obtaining a bispecific antigen-binding molecule, kits for encoding and obtaining a bispecific antigen-binding molecule, an immunoconjugate and a composition for treating or slowing the progression of HER2-positive cancer, a method of treating or slowing progression of HER2 positive cancer in a subject, a method of enhancing immune function in a subject having HER2 positive cancer, and a kit for treating or slowing the progression of HER2 positive cancer in a subject.
EFFECT: group of inventions is used for the treatment of pathological conditions such as HER2-positive cancer.
62 cl, 14 tbl, 42 dwg, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
| ANTI-TAU PROTEIN ANTIBODIES AND METHODS OF USING SAID ANTIBODIES | 2016 |
|
RU2732122C2 |
| ANTIBODIES TO DENGUE VIRUS WITH CROSS-REACTIVITY WITH ZIKA VIRUS | 2019 |
|
RU2811697C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
